Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bavarian Nordic smallpox vaccine

Phase 3Vaccine

MMcMaster University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

MonkeypoxActive, not recruiting

MonkeypoxPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

ApprovedActive, not recruiting

Monkeypox

NCT05745987

Clinical

Trials by Indication[1]

Monkeypox1 trial

SMART (Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster Randomized Controlled Trial)

Active, not recruiting·MMcMaster University·Approved·NCT05745987·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bavarian Nordic smallpox vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bavarian Nordic smallpox vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bavarian Nordic smallpox vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — McMaster University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: MMcMaster University

Related News